Last reviewed · How we verify
Vancomycin with Taper/Pulse
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, and a taper/pulse dosing regimen modulates exposure to reduce toxicity while maintaining efficacy.
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, and a taper/pulse dosing regimen modulates exposure to reduce toxicity while maintaining efficacy. Used for Serious gram-positive bacterial infections (e.g., methicillin-resistant Staphylococcus aureus, MRSA), Clostridium difficile infection, Endocarditis.
At a glance
| Generic name | Vancomycin with Taper/Pulse |
|---|---|
| Sponsor | VA Office of Research and Development |
| Drug class | Glycopeptide antibiotic |
| Target | Bacterial peptidoglycan (D-Ala-D-Ala) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vancomycin is a glycopeptide antibiotic that prevents cross-linking of peptidoglycan in bacterial cell walls, leading to cell lysis and death. The taper/pulse dosing strategy involves gradually reducing or intermittently administering the drug to minimize cumulative nephrotoxicity and ototoxicity while preserving antimicrobial activity, particularly useful in chronic or recurrent infections.
Approved indications
- Serious gram-positive bacterial infections (e.g., methicillin-resistant Staphylococcus aureus, MRSA)
- Clostridium difficile infection
- Endocarditis
Common side effects
- Nephrotoxicity (acute kidney injury)
- Ototoxicity (hearing loss)
- Red man syndrome (flushing, pruritus)
- Phlebitis at infusion site
- Fever
Key clinical trials
- Optimal Treatment for Recurrent Clostridium Difficile (PHASE4)
- Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
- Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vancomycin with Taper/Pulse CI brief — competitive landscape report
- Vancomycin with Taper/Pulse updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI